Results 1 to 10 of about 93,929 (247)

Sorafenib and Sunitinib [PDF]

The Oncologist, 2009
Learning Objectives After completing this course, the reader will be able to: Enumerate the clinical indications for sorafenib and sunitinib therapy.Describe the mechanism of action and the pharmacokinetics of sorafenib and sunitinib.Analyze the toxicity profile and appraise the therapeutic effects associated with sorafenib and sunitinib.
AeRang, Kim, Frank M, Balis, Brigitte C, Widemann   +2 more
openaire   +2 more sources

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [PDF]

, 2018
Background: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs.
Deptala, A, Fartoux, L, Graham, J, Hocke, J, Loembé, A-B, Ma, Y T, Meyer, T, Palmer, D H, Peck-Radosavljevic, M, Ross, P, Schnell, D, Studeny, M   +11 more
core   +3 more sources

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]

, 2017
Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W, Duan, Zhijian, Ho, Pui Yan, Jian, Chao, Lam, Kit S, Lara, Primo N, Qiu, Jing-Xin, Tu, Mei-Juan, Wun, Theodore, Yu, Ai-Ming, Yu, Ai-Xi, Zhang, Qianyu   +11 more
core   +1 more source

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. [PDF]

, 2016
Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options.
Alanis, Lourdes, Cho, Sung-Ki, Lee, Edward Wolfgang, Saab, Sammy   +3 more
core   +1 more source

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. [PDF]

, 2019
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options.
Calvisi, Diego F, Che, Li, Chen, Xin, Evert, Matthias, Hu, Junjie, Liu, Xianqiong, Lu, Xinjun, Song, Xinhua, Su, Tao, Utpatel, Kirsten, Wang, Jingxiao, Wang, Pan, Xu, Meng, Zhang, Jie, Zhang, Yi   +14 more
core   +1 more source

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. [PDF]

, 2014
Hypertension after treatment with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients.
Bakris, GL, Cohen, EEW, Fleming, GF, House, LK, Karovic, S, Karrison, TG, Levine, MR, Maitland, ML, Ratain, MJ, Rudek, MA, Thomeas, V, Wen, Y, Wright, JJ, Wu, K   +13 more
core   +2 more sources

Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence [PDF]

, 2019
Hepatocellular carcinoma (HCC) is a leading cause of new cancer diagnoses in the United States, with an incidence that is expected to rise. The etiology of HCC is varied and can lead to differences between patients in terms of presentation and natural ...
Gholam, Pierre M., Iyer, Renuka, Johnson, Matthew S.   +2 more
core   +1 more source

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]

, 2015
Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W, Faltermeier, Claire, Zarrinpar, Ali   +2 more
core   +2 more sources

Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]

, 2015
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján, Mathet, Veronica Lidia, Oubiña, Jose Raul   +2 more
core   +1 more source

Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. [PDF]

, 2016
Osteosarcoma occurs mostly in children and young adults, who are treated with multiple agents in combination with limb-salvage surgery. However, the overall 5-year survival rate for patients with recurrent or metastatic osteosarcoma is 20-30% which has ...
Chishima, Takashi, Dry, Sarah M, Eilber, Fritz C, Elliott, Irmina, Endo, Itaru, Federman, Noah, Hiroshima, Yukihiko, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Yunfeng, Matsuyama, Ryusei, Murakami, Takashi, Nelson, Scott D, Russell, Tara, Singh, Arun, Tanaka, Kuniya, Yanagawa, Jane, Zhang, Yong, Zhao, Ming   +20 more
core   +2 more sources